Q1 2018 · —
Revenue$5.79M$5.79M −61.0% vs Q1 2017+43.4% vs Q4 2017
Net Income-$12.05M-$12.05M N/M vs Q1 2017N/M vs Q4 2017
EPS Diluted-$25.76-$25.76 N/M vs Q1 2017N/M vs Q4 2017
Operating Income-$11,703,000—
Operating Cash Flow-$15,010,000—
Free Cash Flowderived-$15,374,000—
Margins · derived
Operating margin-202.0%
Net margin-207.9%−200.4 pt vs Q1 2017
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2018 | Q1 2017 |
|---|---|---|
| Revenue | $5.79M | $14.85M |
| Net Income | -$12.05M | -$1.11M |
| EPS Diluted | -$25.76 | -$2.55 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR